Drug Trial Radar · NCT07285304
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Jul 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
Conditions
- Hyperphosphatemia Patients on Hemodialysis
Interventions
TS-172Drug
oral administration of TS-172 20\~60 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 26 weeks or up to 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.